OMP-18R5 and OMP-54F28 (inhibitors of the Wnt/β-catenin signaling pathway), LED225 (a Hh inhibitor), and LY2157299 (a TGF-β inhibitor) are progressing to clinical trials alone or in combination with other chemotherapeutic agents targeting LCSCs of HCC [133]. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.